chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Sex: M
Vaccine: VARZOS
Symptoms: Herpes zoster
Clinical narrative: Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. In 2007, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided) to obtain permanent prevention and protection against shingles and zoster related injuries. In 2015, the patient was treated by a physician for shingles. The patient was diagnosed with shingles and/or other zoster-related injuries after and despite being inoculated with the ZOSTAVAX, and suffered serious physical, emotional, and economic damages as a result of the patient's injuries. As a direct and proximate result of the ZOSTAVAX vaccine, the patient has and will continue to suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; extensive medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs including care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; a diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; lost wages; loss of earnings capacity; and other losses and damages. The outcome of the events was considered to be not recovered. Additional information has been requested.
Age: 14.0
Sex: M
Vaccine: FLUN3
Symptoms: Influenza, Pyrexia, Urticaria
Clinical narrative: A spontaneous report has been received from a consumer. The report concerns a male patient (age 14 years, weight 90 lb). No medical history was reported. No concomitant products were reported.  The patient received FLUMIST (influenza vaccine (live, attenuated)) yearly, via nasal route, start date ages 5 to 13 annually until approximately 2015 or 2016. A day or 2 after receiving the flu shot in 2017, the patient had hand sized welts on chest/ hand size welts on both arms. Treatment prescribed was steroid cream 1 or 2 times a day and welts went away. The HCP stated the reaction was to the eggs. At the time of Flu shot the son was 5 feet or 5 feet 1 inch and weighed 90 pounds. The patient had flu strain a and fever for 3 or 4 days with flu in Jan or Feb-2018 as diagnosed at Urgent care by a swab test. Patient was prescribed Tamiflu for 1 week, dose and frequency are unknown. Treatment with FLUMIST (influenza vaccine (live, attenuated)) was not changed. The patient recovered from the event(s) of flu strain a, fever for 3 or 4 days with flu and hand sized welts on chest/ hand size welts on both arms on an unspecified date. The events were considered non-serious.
Sex: U
Vaccine: VARZOS
Symptoms: Adverse drug reaction
Clinical narrative: This case was reported by a consumer and described the occurrence of adverse drug reaction in a patient who received SHINGRIX for prophylaxis. On an unknown date, the patient received the 1st dose of SHINGRIX. On an unknown date, unknown after receiving SHINGRIX, the patient experienced adverse drug reaction. On an unknown date, the outcome of the adverse drug reaction was unknown. It was unknown if the reporter considered the adverse drug reaction to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient stated that, if he suffered from all the side effects except a fever with 1st dose of the 2 part shingles vaccination and would be he had same side effects after the 2nd vaccination.
Sex: U
Vaccine: FLU4
Symptoms: Influenza, Influenza virus test positive, Vaccination failure
Clinical narrative: This case was reported by a other health professional via sales rep and described the occurrence of vaccination failure in a child patient who received FLUARIX QUADRIVALENT 2018-2019 season for prophylaxis. On an unknown date, the patient received FLUARIX QUADRIVALENT 2018-2019 season at an unknown dose. On an unknown date, less than a year after receiving FLUARIX QUADRIVALENT 2018-2019 season, the patient experienced vaccination failure (serious criteria GSK medically significant) and influenza. On an unknown date, the outcome of the vaccination failure and influenza were unknown. It was unknown if the reporter considered the vaccination failure and influenza to be related to FLUARIX QUADRIVALENT 2018-2019 season. Additional details were received as follows: The age at vaccination was not reported. The office reported that the patient who received FLUARIX vaccine resulted positive for influenza. This case was considered as suspected vaccination failure case since the time to onset were unknown at the time reporting. The reporter did not agree to follow up from GlaxoSmithKline. This case was linked with US2019GSK000801 and US2019GSK000802, reported by the same reporter. Lab Comments: On an unknown date, the patient did laboratory test.